Mogamulizumab-induced interface dermatitis drug rash treated successfully with methotrexate and extracorporeal photopheresis in a patient with Sézary syndrome

Ilana D Breen; Caitlin M Brumfiel; Meera H Patel; Allison C Rosenthal; William G Rule; David J DiCaudo; Fiona E Craig; Mark R Pittelkow; Aaron R Mangold

doi:10.1016/j.jdcr.2020.12.035

Mogamulizumab-induced interface dermatitis drug rash treated successfully with methotrexate and extracorporeal photopheresis in a patient with Sézary syndrome

JAAD Case Rep. 2021 Jan 12:9:24-27. doi: 10.1016/j.jdcr.2020.12.035. eCollection 2021 Mar.

Authors

Ilana D Breen¹, Caitlin M Brumfiel², Meera H Patel², Allison C Rosenthal³, William G Rule⁴, David J DiCaudo^{2

5}, Fiona E Craig⁵, Mark R Pittelkow², Aaron R Mangold²

Affiliations

¹ Mayo Clinic Alix School of Medicine, Scottsdale, Arizona.
² Mayo Clinic Arizona, Dermatology, Scottsdale, Arizona.
³ Mayo Clinic Arizona, Hematology Oncology, Phoenix, Arizona.
⁴ Mayo Clinic Arizona, Radiation Oncology, Phoenix, Arizona.
⁵ Mayo Clinic Arizona, Laboratory Medicine and Pathology, Phoenix, Arizona.

No abstract available

Keywords: CCR4, C-C chemokine receptor 4; Cutaneous T-cell lymphoma; ECP, extracorporeal photopheresis; MF, mycosis fungoides; SS, Sézary syndrome; Sézary; extracorporeal photopheresis; interface dermatitis; methotrexate; mogamulizumab.

Publication types

Case Reports